160 results on '"Mann, GB"'
Search Results
2. Spotlight on the utility of the Oncotype DX® breast cancer assay
- Author
-
Siow ZR, De Boer RH, Lindeman GJ, and Mann GB
- Subjects
Breast cancer ,adjuvant ,Oncotype DX® ,Recurrence Score ,Utility ,Gynecology and obstetrics ,RG1-991 - Abstract
Zhen Rong Siow,1–3 Richard H De Boer,2,3 Geoffrey J Lindeman,1–4 G Bruce Mann2–4 1ACRF Stem Cells and Cancer Division, Walter and Eliza Hall Institute of Medical Research, 2Department of Medical Oncology, Peter MacCallum Cancer Centre, 3Familial Cancer Centre, The Royal Melbourne Hospital, 4Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Parkville, VIC, Australia Abstract: The Oncotype DX® assay was developed to address the need for optimizing the selection of adjuvant systemic therapy for patients with estrogen receptor (ER)-positive, lymph node-negative breast cancer. It has ushered in the era of genomic-based personalized cancer care for ER-positive primary breast cancer and is now widely utilized in various parts of the world. Together with several other genomic assays, Oncotype DX has been incorporated into clinical practice guidelines on biomarker use to guide treatment decisions. The Oncotype DX result is presented as the recurrence score which is a continuous score that predicts the risk of distant disease recurrence. The assay, which provides information on clinicopathological factors, has been validated for use in the prognostication and prediction of degree of adjuvant chemotherapy benefit in both lymph node-positive and lymph node-negative early breast cancers. Clinical studies have consistently shown that the Oncotype DX has a significant impact on decision making in adjuvant therapy recommendations and appears to be cost-effective in diverse health care settings. In this article, we provide an overview of the validation and clinical impact studies for the Oncotype DX assay. We also discuss its potential use in the neoadjuvant setting, as well as the more recent prospective validation trials, and the economic and utility implications of studies that use a lower cutoff score to define low-risk disease. Keywords: breast cancer, adjuvant, Oncotype DX®, recurrence score, utility
- Published
- 2018
3. Identification of copy number alterations associated with the progression of DCIS to invasive ductal carcinoma
- Author
-
Johnson C, Gorringe KL, Thompson ER, Opeskin K, Boyle SE, Wang Y, Hill P, Mann GB, and Campbell IG
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 ,Genetics ,QH426-470 - Published
- 2012
- Full Text
- View/download PDF
4. Erratum to:Methods for evaluating medical tests and biomarkers
- Author
-
Gopalakrishna, G, Langendam, M, Scholten, R, Bossuyt, P, Leeflang, M, Noel-Storr, A, Thomas, J, Marshall, I, Wallace, B, Whiting, P, Davenport, C, GopalaKrishna, G, De Salis, I, Mallett, S, Wolff, R, Riley, R, Westwood, M, Kleinen, J, Collins, G, Reitsma, H, Moons, K, Zapf, A, Hoyer, A, Kramer, K, Kuss, O, Ensor, J, Deeks, JJ, Martin, EC, Riley, RD, Rücker, G, Steinhauser, S, Schumacher, M, Snell, K, Willis, B, Debray, T, Deeks, J, Di Ruffano, LF, Taylor-Phillips, S, Hyde, C, Taylor, SA, Batnagar, G, STREAMLINE COLON Investigators, STREAMLINE LUNG Investigators, METRIC Investigators, Seedat, F, Clarke, A, Byron, S, Nixon, F, Albrow, R, Walker, T, Deakin, C, Zhelev, Z, Hunt, H, Yang, Y, Abel, L, Buchanan, J, Fanshawe, T, Shinkins, B, Wynants, L, Verbakel, J, Van Huffel, S, Timmerman, D, Van Calster, B, Zwinderman, A, Oke, J, O'Sullivan, J, Perera, R, Nicholson, B, Bromley, HL, Roberts, TE, Francis, A, Petrie, D, Mann, GB, Malottki, K, Smith, H, Billingham, L, Sitch, A, Gerke, O, Holm-Vilstrup, M, Segtnan, EA, Halekoh, U, Høilund-Carlsen, PF, Francq, BG, Dinnes, J, Parkes, J, Gregory, W, Hewison, J, Altman, D, Rosenberg, W, Selby, P, Asselineau, J, Perez, P, Paye, A, Bessede, E, Proust-Lima, C, Naaktgeboren, C, De Groot, J, Rutjes, A, Reitsma, J, Ogundimu, E, Cook, J, Le Manach, Y, Vergouwe, Y, Pajouheshnia, R, Groenwold, R, Peelen, L, Nieboer, D, De Cock, B, Pencina, MJ, Steyerberg, EW, Cooper, J, Parsons, N, Stinton, C, Smith, S, Dickens, A, Jordan, R, Enocson, A, Fitzmaurice, D, Adab, P, Boachie, C, Vidmar, G, Freeman, K, Connock, M, Court, R, Moons, C, Harris, J, Mumford, A, Plummer, Z, Lee, K, Reeves, B, Rogers, C, Verheyden, V, Angelini, GD, Murphy, GJ, Huddy, J, Ni, M, Good, K, Cooke, G, Hanna, G, Ma, J, Moons, KGMC, De Groot, JAH, Altman, DG, Reitsma, JB, Collins, GS, Moons, KGM, Kamarudin, AN, Kolamunnage-Dona, R, Cox, T, Borsci, S, Pérez, T, Pardo, MC, Candela-Toha, A, Muriel, A, Zamora, J, Sanghera, S, Mohiuddin, S, Martin, R, Donovan, J, Coast, J, Seo, MK, Cairns, J, Mitchell, E, Smith, A, Wright, J, Hall, P, Messenger, M, Calder, N, Wickramasekera, N, Vinall-Collier, K, Lewington, A, Damen, J, Cairns, D, Hutchinson, M, Sturgeon, C, Mitchel, L, Kift, R, Christakoudi, S, Rungall, M, Mobillo, P, Montero, R, Tsui, T-L, Kon, SP, Tucker, B, Sacks, S, Farmer, C, Strom, T, Chowdhury, P, Rebollo-Mesa, I, Hernandez-Fuentes, M, Damen, JAAG, Debray, TPA, Heus, P, Hooft, L, Scholten, RJPM, Schuit, E, Tzoulaki, I, Lassale, CM, Siontis, GCM, Chiocchia, V, Roberts, C, Schlüssel, MM, Gerry, S, Black, JA, Van der Schouw, YT, Peelen, LM, Spence, G, McCartney, D, Van den Bruel, A, Lasserson, D, Hayward, G, Vach, W, De Jong, A, Burggraaff, C, Hoekstra, O, Zijlstra, J, De Vet, H, Graziadio, S, Allen, J, Johnston, L, O'Leary, R, Power, M, Johnson, L, Waters, R, Simpson, J, Fanshawe, TR, Phillips, P, Plumb, A, Helbren, E, Halligan, S, Gale, A, Sekula, P, Sauerbrei, W, Forman, JR, Dutton, SJ, Takwoingi, Y, Hensor, EM, Nichols, TE, Kempf, E, Porcher, R, De Beyer, J, Hopewell, S, Dennis, J, Shields, B, Jones, A, Henley, W, Pearson, E, Hattersley, A, MASTERMIND consortium, Scheibler, F, Rummer, A, Sturtz, S, Großelfinger, R, Banister, K, Ramsay, C, Azuara-Blanco, A, Burr, J, Kumarasamy, M, Bourne, R, Uchegbu, I, Murphy, J, Carter, A, Marti, J, Eatock, J, Robotham, J, Dudareva, M, Gilchrist, M, Holmes, A, Monaghan, P, Lord, S, StJohn, A, Sandberg, S, Cobbaert, C, Lennartz, L, Verhagen-Kamerbeek, W, Ebert, C, Horvath, A, Test Evaluation Working Group of the European Federation of Clinical Chemistry and Laboratory Medicine, Jenniskens, K, Peters, J, Grigore, B, Ukoumunne, O, Levis, B, Benedetti, A, Levis, AW, Ioannidis, JPA, Shrier, I, Cuijpers, P, Gilbody, S, Kloda, LA, McMillan, D, Patten, SB, Steele, RJ, Ziegelstein, RC, Bombardier, CH, Osório, FDL, Fann, JR, Gjerdingen, D, Lamers, F, Lotrakul, M, Loureiro, SR, Löwe, B, Shaaban, J, Stafford, L, Van Weert, HCPM, Whooley, MA, Williams, LS, Wittkampf, KA, Yeung, AS, Thombs, BD, Cooper, C, Nieto, T, Smith, C, Tucker, O, Dretzke, J, Beggs, A, Rai, N, Bayliss, S, Stevens, S, Mallet, S, Sundar, S, Hall, E, Porta, N, Estelles, DL, De Bono, J, CTC-STOP protocol development group, and National Institute for Health Research
- Subjects
medicine.medical_specialty ,Astrophysics::High Energy Astrophysical Phenomena ,MEDLINE ,030204 cardiovascular system & hematology ,BTC (Bristol Trials Centre) ,MASTERMIND consortium ,03 medical and health sciences ,0302 clinical medicine ,medicine ,030212 general & internal medicine ,Intensive care medicine ,CTC-STOP protocol development group ,lcsh:R5-920 ,business.industry ,Test Evaluation Working Group of the European Federation of Clinical Chemistry and Laboratory Medicine ,Published Erratum ,STREAMLINE COLON Investigators ,3. Good health ,STREAMLINE LUNG Investigators ,Centre for Surgical Research ,Family medicine ,METRIC Investigators ,High Energy Physics::Experiment ,Erratum ,business ,lcsh:Medicine (General) - Abstract
[This corrects the article DOI: 10.1186/s41512-016-0001-y.].
- Published
- 2017
5. Improved Spillway Efficiency Using a Duckbill Crest - a Case Study
- Author
-
Conference on Hydraulics in Civil Engineering (3rd : 1987 : Melbourne, Vic.), Lesleighter, EJ, Mann, GB, and Harrison, RD
- Published
- 1987
6. The Breast Service Psychosocial Model of Care Project.
- Author
-
Williams LK and Mann GB
- Abstract
Objective: It has been consistently demonstrated that many women with breast disease will experience psychosocial distress at some stage along the patient journey. Psychosocial care has recently gained more prominence and is increasingly recognised as an important aspect of care offered to patients with breast cancer. The purpose of this project was to develop a model that improved the way psychosocial services were provided to patients. The aim of this paper is to describe the process in developing this psychosocial model of care for patients with breast disease. Methods: Using in-depth semi-structured interviews with a sample of patients and staff, we examined psychosocial concerns experienced by breast patients and the factors associated with the effective assessment and delivery of psychosocial care. The project was approved by the Royal Women's hospital ethics secretariat as a quality assurance project. Results: An inductive analysis of staff responses indicated that a standardised screening and referral pathway was needed in a context of well defined staff roles and a multidisciplinary team environment. An inductive analysis of patient responses indicated that psychosocial concerns were common, but varied, and a tailored approach to the provision of psychosocial care was warranted. Discussion: In line with these findings, a standardised assessment and referral pathway was developed for The Breast Service that may be extended for use in other clinical settings and tumour streams. [ABSTRACT FROM AUTHOR]
- Published
- 2009
7. Secondary causes of low bone mass in patients with breast cancer: a need for greater vigilance.
- Author
-
Mann GB, Kang YC, Brand C, Ebeling PR, and Miller JA
- Published
- 2009
- Full Text
- View/download PDF
8. Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group.
- Author
-
Testori A, Richards J, Whitman E, Mann GB, Lutzky J, Camacho L, Parmiani G, Tosti G, Kirkwood JM, Hoos A, Yuh L, Gupta R, Srivastava PK, C-100-21 Study Group, Testori, Alessandro, Richards, Jon, Whitman, Eric, Mann, G Bruce, Lutzky, Jose, and Camacho, Luis
- Published
- 2008
- Full Text
- View/download PDF
9. Breast conservation versus mastectomy in triple-negative breast cancer: two steps forward, one step back?
- Author
-
Trainer AH, James PA, Mann GB, and Lindeman GJ
- Published
- 2011
- Full Text
- View/download PDF
10. Incorporation of evidence-based principles in baccalaureate and nonbaccalaureate degree dental hygiene programs.
- Author
-
Chichester SR, Wilder RS, Mann GB, and Neal E
- Abstract
PURPOSE: The purpose of this descriptive study was to determine the curricular utilization of Evidence-Based (EB) philosophies in dental hygiene education in both baccalaureate and nonbaccalaureate U.S. dental hygiene programs. METHODS: Data were gathered via a 1999 survey of all 235 U.S. dental hygiene program directors. The 21-question survey included one open-ended and 20 closed-ended items. Initially, the survey was pilot tested using a convenience sample of seven U.S. dental hygiene program directors. A final, revised survey was mailed to the cohort population. A response rate of 71% (N = 167) was achieved after two mailings. RESULTS: The demographic results of this study revealed the majority of respondents (77%) were from nonbaccalaureate dental hygiene programs, while the remainder (23%) were from baccalaureate degree programs. Respondents were asked if and to what degree the fundamentals of research were taught in their curriculum. Baccalaureate programs' responses indicated a much greater degree of utilization. Sixty-two percent of baccalaureate respondents provide a separate course on research, and 32% teach research as a portion of another dental hygiene course. However, 3% of the responding baccalaureate programs reported that no research was included in the curriculum. These results demonstrate an overall high utilization of research by baccalaureate curricula. In comparison, nonbaccalaureate programs' responses show a lesser degree of research utilization when compared with the baccalaureate programs. Only 8% of nonbaccalaureate programs had a separate research course. The majority, 80%, of nonbaccalaureate respondents reported that they teach research as a portion of another dental hygiene course. Finally, 10% of the nonbaccalaureate degree respondents reported teaching no research. Overwhelmingly, both baccalaureate and nonbaccalaureate students received formal orientation in the use of library--100% and 84%, respectively. Ninety-seven percent of baccalaureate and 82% of nonbaccalaureate programs provided students with formal instruction in using both literature indices and databases. To a lesser extent, both baccalaureate and nonbaccalaureate programs introduced students to the Internet and encouraged them to use it for conducting literature searches--83% and 78%, respectively. In fact, seventy-four percent of baccalaureate programs and 68% of nonbaccalaureate programs reported formally teaching the evaluation of information retrieved from the Internet. Both baccalaureate and nonbaccalaureate programs similarly indicated teaching the evaluation of research findings for validity, reliability, and clinical importance. To a lesser extent, 86% of baccalaureate and 61% of nonbaccalaureate programs reported that they encourage students to make EB recommendations to patients and teach students how to apply EB findings to clinical situations. CONCLUSION: The findings of this descriptive study indicate both baccalaureate and nonbaccalaureate degree programs incorporate some aspects of an EB philosophy into the curriculum. Survey results reveal baccalaureate degree programs incorporated research and taught the use of library facilities, journal indices, and electronic databases. In addition, baccalaureate degree programs also emphasized and encouraged the application of critically appraised evidence into practice. The nonbaccalaureate respondents utilized the library facilities, journal indices, and electronic databases to a slightly lesser extent than their baccalaureate counterparts. The nonbaccalaureate respondents also demonstrated less application of EB findings to clinical situations, including actual patient treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2002
11. Utilization of evidence-based teaching in U.S. dental hygiene curricula.
- Author
-
Chichester SR, Wilder RS, Mann GB, and Neal E
- Abstract
Purpose. The purpose of this research was to survey U.S. dental hygiene program directors to determine: (1) demographic information, (2) specific Evidence-Based (EB) student instruction methods used, (3) if and how f programs use an EB philosophy, (4) perceptions of faculty skills in incorporating EB instruction, and (5) opinions and attitudes regarding future; need to incorporate EB philosophies in dental hygiene education.Methods. Data were gathered by surveying all 235 United States dental hygiene program directors in 1999. The survey included 20 closed items and 1 open-ended item. Initially, the survey was pilot tested using , a convenience sample of seven U.S. dental hygiene program directors. A final, revised survey was mailed to the cohort population. A response rate of 70% (n=164) was achieved after two mailings, and responses were analyzed using descriptive statistics.Results. The demographic results of this study revealed the majority of respondents were from associate degree/certificate dental hygiene programs (77%). Results revealed that most dental hygiene programs are beginning to include some fundamental EB concepts and skills into their curriculum, primarily by incorporating analysis of scientific literature. Most programs provide students with formal library orientation (88%), instruct students in the use of library indices or library databases (86%), and teach the use of the Internet for conducting literature searches (79%). Respondents indicated the major barriers for fully incorporating an EB approach in their dental hygiene program were: lack of faculty skills (37%), no available time (34%), lack of financial resources (33%), and lack of technical support (28%).Conclusion. Findings of this study suggest dental hygiene educators have made small strides in creating an EB philosophy dental hygiene curriculum. However, the future of dental hygiene education must address the need for faculty development and training in areas such as computer utilization in core dental hygiene courses, strategies to improve the curriculum to stimulate students' critical thinking skills, and to develop educators' skills in the use of evidence for clinical decision-making. [ABSTRACT FROM AUTHOR]
- Published
- 2001
12. Adjuvant chemoradiation for gastric cancer using epirubicin, Cisplatin, and 5-Fluorouracil before and after three-dimensional conformal radiotherapy with concurrent infusional 5-Fluorouracil: a multicenter study of the trans-tasman radiation oncology group.
- Author
-
Leong T, Joon DL, Willis D, Jayamoham J, Spry N, Harvey J, Di Iulio J, Milner A, Mann GB, and Michael M
- Published
- 2011
- Full Text
- View/download PDF
13. Stromal lymphocytes are associated with upgrade of B3 breast lesions.
- Author
-
Kader T, Provenzano E, Jayawardana MW, Hendry S, Pang JM, Elder K, Byrne DJ, Tjoeka L, Frazer HM, House E, Jayasinghe SI, Keane H, Murugasu A, Rajan N, Miligy IM, Toss M, Green AR, Rakha EA, Fox SB, Mann GB, Campbell IG, and Gorringe KL
- Subjects
- Humans, Female, Middle Aged, Aged, Adult, Neoplasm Grading, Lymphocytes, Tumor-Infiltrating immunology, Lymphocytes, Tumor-Infiltrating metabolism, Carcinoma, Intraductal, Noninfiltrating pathology, Carcinoma, Intraductal, Noninfiltrating immunology, Carcinoma, Ductal, Breast pathology, Carcinoma, Ductal, Breast immunology, Biomarkers, Tumor, Breast Neoplasms pathology, Breast Neoplasms immunology, Tumor Microenvironment immunology, Lymphocytes immunology, Lymphocytes pathology, Stromal Cells pathology
- Abstract
Various histopathological, clinical and imaging parameters have been evaluated to identify a subset of women diagnosed with lesions with uncertain malignant potential (B3 or BIRADS 3/4A lesions) who could safely be observed rather than being treated with surgical excision, with little impact on clinical practice. The primary reason for surgery is to rule out an upgrade to either ductal carcinoma in situ or invasive breast cancer, which occurs in up to 30% of patients. We hypothesised that the stromal immune microenvironment could indicate the presence of carcinoma associated with a ductal B3 lesion and that this could be detected in biopsies by counting lymphocytes as a predictive biomarker for upgrade. A higher number of lymphocytes in the surrounding specialised stroma was observed in upgraded ductal and papillary B3 lesions than non-upgraded (p < 0.01, negative binomial model, n = 307). We developed a model using lymphocytes combined with age and the type of lesion, which was predictive of upgrade with an area under the curve of 0.82 [95% confidence interval 0.77-0.87]. The model can identify some patients at risk of upgrade with high sensitivity, but with limited specificity. Assessing the tumour microenvironment including stromal lymphocytes may contribute to reducing unnecessary surgeries in the clinic, but additional predictive features are needed., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
14. Contrast-enhanced mammography for surveillance in women with a personal history of breast cancer.
- Author
-
Matheson J, Elder K, Nickson C, Park A, Mann GB, and Rose A
- Abstract
Purpose: Women with a personal history of breast cancer have an increased risk of subsequent breast malignancy and may benefit from more sensitive surveillance than conventional mammography (MG). We previously reported outcomes for first surveillance episode using contrast-enhanced mammography (CEM), demonstrating higher sensitivity and comparable specificity to MG. We now report CEM performance for subsequent surveillance., Methods: A retrospective study of 1,190 women in an Australian hospital setting undergoing annual surveillance following initial surveillance CEM between June 2016 and December 2022. Outcome measures were recall rate, cancer detection rate, contribution of contrast to recalls, false positive rate, interval cancer rate and characteristics of surveillance detected and interval cancers., Results: 2,592 incident surveillance episodes were analysed, of which 93% involved contrast-based imaging. Of 116 (4.5%) recall episodes, 40/116 (34%) recalls were malignant (27 invasive; 13 ductal carcinoma in situ), totalling 15.4 cancers per 1000 surveillance episodes. 55/116 (47%) recalls were contrast-directed including 17/40 (43%) true positive recalls. Tumour features were similar for contrast-directed recalls and other diagnoses. 8/9 (89%) of contrast-directed invasive recalls were Grade 2-3, and 5/9 (56%) were triple negative breast cancers. There were two symptomatic interval cancers (0.8 per 1000 surveillance episodes, program sensitivity 96%)., Conclusion: Routine use of CEM in surveillance of women with PHBC led to an increase in the detection of clinically significant malignant lesions, with a low interval cancer rate compared to previous published series. Compared to mammographic surveillance, contrast-enhanced mammography increases the sensitivity of surveillance programs for women with PHBC., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
15. Quality of Life Outcomes Associated With Optimization of Treatment by Omitting Radiotherapy in Early Breast Cancer.
- Author
-
Stafford L, Sinclair M, Butow P, Hughes J, Park A, Gilham L, Rose A, and Mann GB
- Subjects
- Humans, Female, Middle Aged, Retrospective Studies, Aged, Adult, Prognosis, Radiotherapy, Adjuvant methods, Body Image psychology, Breast Neoplasms radiotherapy, Breast Neoplasms psychology, Breast Neoplasms pathology, Breast Neoplasms surgery, Quality of Life, Magnetic Resonance Imaging, Mastectomy, Segmental psychology
- Abstract
Purpose: Improved prognosis of early breast cancer (EBC) has created opportunities for treatment optimization but reducing morbidity should not inadvertently compromise quality of life (QoL). PROSPECT
1 used pre-operative MRI and pathology findings to identify women suitable for radiotherapy (RT) omission following breast conserving surgery. We retrospectively explored the association between de-escalation by omission of RT and QoL in women with EBC., Materials and Methods: Three groups were recruited: PROSPECT participants who omitted RT following preoperative MRI (A); participants who received RT following preoperative MRI (B); and women who received usual care - No MRI, received RT (C). Measures included the EORTC QLQ-C30 and BR23, BCTOS, DASS-21 and a measure of decision regret. Between group differences were assessed using ANOVA or nonparametric equivalents. Semi-structured interviews were analyzed with qualitative description (n = 44)., Results: Data from 400 women were analyzed (125A, 102B, 173C). Group A had fewer symptoms and better body image (breast symptoms: A-B P = .003, A-C P = <.001; arm symptoms: A-B P = .004, A-C P = .011; body image: A-C P = .041) and fewer differences between the treated and untreated breasts (cosmetic: A-B P < .001, A-C P < .001; functional: A-C P = .011; breast specific pain: A-B P < .001, A-C P < .001). Two qualitative themes were found: Treatment with the biggest impact on QoL, and Specific impact of RT on QoL., Conclusions: Omission of RT was associated with better QoL and functional and cosmetic outcomes. It was highly acceptable to patients. Clinicians should consider the potential for preserved QoL associated with treatment optimization via omission of RT in treatment planning for patients with EBC., Competing Interests: Disclosure The authors have no competing interests to declare. The authors have no relevant financial or non-financial interests to disclose., (Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
16. What About This IDEA: The PROSPECT That Occult Malignant Lesions May Explain Local Recurrences in Very Early Breast Cancer?
- Author
-
Mann GB, Rose AK, and Zdenkowski N
- Subjects
- Humans, Female, Breast Neoplasms pathology, Breast Neoplasms therapy, Breast Neoplasms diagnosis, Neoplasm Recurrence, Local
- Published
- 2024
- Full Text
- View/download PDF
17. Autologous Fat Grafting in Breast Augmentation: A Systematic Review Highlighting the Need for Clinical Caution.
- Author
-
Seth I, Bulloch G, Gibson D, Chow O, Seth N, Mann GB, Hunter-Smith DJ, and Rozen WM
- Abstract
Background: Autologous fat grafting (AFG) is a breast augmentation method for treating volume and contour abnormalities. This systematic review aims to summarize complications, radiologic safety, volume retention, and patient satisfaction associated with AFG., Methods: The PubMed, Embase, Google Scholar, Cochrane Central Register of Controlled Trials, Wiley library, clinical key/Elsevier, and EBSCO databases were searched for relevant studies from January of 2009 to March of 2022. Articles describing AFG for breast augmentation were selected based on predetermined inclusion and exclusion criteria. Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines were adhered to, and the study was registered on the International Prospective Register of Systematic Reviews. The Risk of Bias in Nonrandomized Studies of Interventions assessment was used to assess the quality of studies and the risk of bias was measured using the Cochrane Risk of Bias Assessment Tool for Nonrandomized Studies of Interventions., Results: A total of 35 studies comprising 3757 women were included. The average follow-up duration was 24.5 months (range, 1 to 372 months). The overall complication rate was 27.8%, with fat necrosis making up 43.7% of all complications. Average fat volume injected was 300 mL (range, 134 to 610 mL), and average volume retention was 58% (range, 44% to 83%). Volume retention was greater with supplementation of fat with platelet-rich plasma and stromal vascular fraction. The most common radiologic changes were fat necrosis (9.4%) and calcification (1.2%). After 1 year of follow-up, patient satisfaction was, on average, 92% (range, 83.2% to 97.5%). The included studies were of good quality and consisted of a moderate risk of bias., Conclusions: AFG was associated with an overall complication rate of 27.8%. Additional supplementation of fat with platelet-rich plasma and stromal vascular fraction may improve graft survival. Despite poor volume retention being a persistent drawback, patient satisfaction remains high., (Copyright © 2023 by the American Society of Plastic Surgeons.)
- Published
- 2024
- Full Text
- View/download PDF
18. Current bi-national attitudes towards targeted axillary dissection.
- Author
-
Ofri A, Spillane AJ, Baker C, Mann GB, Walker M, and Warrier S
- Subjects
- Humans, Axilla, Neoplasm Staging, Sentinel Lymph Node Biopsy, Lymph Node Excision, Lymph Nodes
- Published
- 2024
- Full Text
- View/download PDF
19. Postoperative radiotherapy omission in selected patients with early breast cancer following preoperative breast MRI (PROSPECT): primary results of a prospective two-arm study.
- Author
-
Mann GB, Skandarajah AR, Zdenkowski N, Hughes J, Park A, Petrie D, Saxby K, Grimmond SM, Murugasu A, Spillane AJ, Chua BH, Badger H, Braggett H, Gebski V, Mou A, Collins JP, and Rose AK
- Subjects
- Female, Humans, Middle Aged, Magnetic Resonance Imaging, Mastectomy, Mastectomy, Segmental methods, Neoplasm Recurrence, Local pathology, Neoplasm Staging, Prospective Studies, Radiotherapy, Adjuvant, Victoria, Aged, Breast Neoplasms diagnostic imaging, Breast Neoplasms radiotherapy, Breast Neoplasms surgery
- Abstract
Background: Adjuvant breast radiotherapy as a standard component of breast-conserving treatment for early cancer can overtreat many women. Breast MRI is the most sensitive modality to assess local tumour burden. The aim of this study was to determine whether a combination of MRI and pathology findings can identify women with truly localised breast cancer who can safely avoid radiotherapy., Methods: PROSPECT is a prospective, multicentre, two-arm, non-randomised trial of radiotherapy omission in patients selected using preoperative MRI and postoperative tumour pathology. It is being conducted at four academic hospitals in Australia. Women aged 50 years or older with cT1N0 non-triple-negative breast cancer were eligible. Those with apparently unifocal cancer had breast-conserving surgery (BCS) and, if pT1N0 or N1mi, had radiotherapy omitted (group 1). Standard treatment including excision of MRI-detected additional cancers was offered to the others (group 2). All were recommended systemic therapy. The primary outcome was ipsilateral invasive recurrence rate (IIRR) at 5 years in group 1. Primary analysis occurred after the 100th group 1 patient reached 5 years follow-up. Quality-adjusted life-years (QALYs) and cost-effectiveness of the PROSPECT pathway were analysed. This study is registered with the Australian New Zealand Clinical Trials Registry (ACTRN12610000810011)., Findings: Between May 17, 2011, and May 6, 2019, 443 patients with breast cancer underwent MRI. Median age was 63·0 years. MRI detected 61 malignant occult lesions separate from the index cancer in 48 patients (11%). Of 201 group 1 patients who had BCS without radiotherapy, the IIRR at 5 years was 1·0% (upper 95% CI 5·4%). In group 1, one local recurrence occurred at 4·5 years and a second at 7·5 years. In group 2, nine patients had mastectomy (2% of total cohort), and the 5-year IIRR was 1·7% (upper 95% CI 6·1%). The only distant metastasis in the entire cohort was genetically distinct from the index cancer. The PROSPECT pathway increased QALYs by 0·019 (95% CI 0·008-0·029) and saved AU$1980 (95% CI 1396-2528) or £953 (672-1216) per patient., Interpretation: PROSPECT suggests that women with unifocal breast cancer on MRI and favourable pathology can safely omit radiotherapy., Funding: Breast Cancer Trials, National Breast Cancer Foundation, Cancer Council Victoria, the Royal Melbourne Hospital Foundation, and the Breast Cancer Research Foundation., Competing Interests: Declaration of interests We declare no competing interests., (Copyright © 2024 Elsevier Ltd. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
20. The complex impact of COVID-19 on cancer outcomes in Australia.
- Author
-
Canfell K, Chiam K, Nickson C, and Mann GB
- Subjects
- Humans, SARS-CoV-2, Australia epidemiology, COVID-19, Neoplasms epidemiology, Neoplasms therapy
- Published
- 2023
- Full Text
- View/download PDF
21. Is de-escalation of treatment by omission of radiotherapy associated with fear of cancer recurrence in women with early breast cancer? An exploratory study.
- Author
-
Stafford L, Sinclair M, Butow P, Hughes J, Park A, Gilham L, Rose A, and Mann GB
- Subjects
- Female, Humans, Adaptation, Psychological, Cross-Sectional Studies, Fear, Radiotherapy, Adjuvant adverse effects, Breast Neoplasms epidemiology, Breast Neoplasms radiotherapy
- Abstract
Purpose: Safe de-intensification of adjuvant radiotherapy (RT) for early breast cancer (BC) is currently under evaluation. Little is known about the patient experience of de-escalation or its association with fear of cancer recurrence (FCR), a key issue in survivorship. We conducted a cross-sectional study to explore this association., Methods: Psychometrically validated measures including the Fear of Cancer Recurrence Inventory-Short Form were completed by three groups of women with early BC: Women in the PROSPECT clinical trial who underwent pre-surgical MRI and omitted RT (A), women who underwent pre-surgical MRI and received RT (B); and women who received usual care (no MRI, received RT; C). Between group differences were analysed with non-parametric tests. A subset from each group participated in a semi-structured interview. These data (n = 44) were analysed with directed content analysis., Results: Questionnaires from 400 women were analysed. Significantly lower FCR was observed in Group A (n = 125) than in Group B (n = 102; p = .002) or Group C (n = 173; p = .001), and when participants were categorized by RT status (omitted RT vs received RT; p < .001). The proportion of women with normal FCR was significantly (p < .05) larger in Group A (62%) than in Group B (35%) or Group C (40%). Two qualitative themes emerged: 'What I had was best' and 'Coping with FCR'., Conclusions: Omitting RT in the setting of the PROSPECT trial was not associated with higher FCR than receiving RT. Positive perceptions about tailored care, lower treatment burden, and trust in clinicians appear to be protective against FCR., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
22. Outcome of different radiotherapy strategies after breast conserving surgery in patients with ductal carcinoma in situ (DCIS).
- Author
-
Wärnberg F, Wadsten C, Karakatsanis A, Olofsson Bagge R, Holmberg E, Lindman H, Sawyer E, Vicini F, Mann GB, and Karlsson P
- Subjects
- Humans, Female, Mastectomy, Segmental, Radiotherapy, Adjuvant, Neoplasm Recurrence, Local surgery, Carcinoma, Intraductal, Noninfiltrating surgery, Carcinoma in Situ pathology, Radiation Oncology, Breast Neoplasms surgery, Carcinoma, Ductal, Breast pathology
- Abstract
Background: Adjuvant radiotherapy (RT) after breast-conserving surgery for DCIS lowers the relative local recurrence risk by half. To identify a low-risk group with the minimal benefit of RT could avoid side effects and spare costs. In this study, the outcome was compared for different RT-strategies using data from the randomized SweDCIS trial., Material and Methods: Five strategies were compared in a Swedish setting: RT-to-none or all, RT to high-risk women defined by DCISionRT, modified Radiation Therapy Oncology Group (RTOG) 9804 criteria, and Swedish Guidelines. Ten-year recurrence risks and cost including adjuvant RT and local recurrence treatment cost were calculated., Results: The mean age at recurrence was 64.4 years (36-90) and the mean cost for treating a recurrence was $21,104. In the SweDCIS cohort ( n = 504), 59 women developed DCIS, and 31 invasive recurrence. Ten-year absolute local recurrence risk (invasive and DCIS) according to different strategies varied between 18.6% (12.5-23.6%) and 7.8% (5.0-12.6%) for RT-to-none or to-all, with an additional cost of $2614 US dollars per women and $24,201 per prevented recurrence for RT-to-all. The risk differences between other strategies were not statistically significant, but the larger proportion receiving RT, the fewer recurrences. DCISionRT spared 48% from RT with 8.1% less recurrences compared to RT-to-none, and a cost of $10,534 per prevented recurrence with additional cost depending on the price of the test. RTOG 9804 spared 39% from RT, with 9.7% less recurrences, $9525 per prevented recurrence and Swedish Guidelines spared 13% from RT, with 10.0% less recurrences, and $21,521 per prevented recurrence., Conclusion: It seems reasonable to omit RT in pre-specified low-risk groups with minimal effect on recurrence risk. Costs per prevented recurrence varied more than two-fold but which strategy that could be considered most cost-effective needs to be further evaluated, including the DCISionRT-test price.
- Published
- 2023
- Full Text
- View/download PDF
23. Impact of a risk based breast screening decision aid on understanding, acceptance and decision making.
- Author
-
Lippey J, Keogh L, Campbell I, Mann GB, and Forrest LE
- Abstract
Internationally, population breast cancer screening is moving towards a risk-stratified approach and requires engagement and acceptance from current and future screening clients. A decision aid ( www.defineau.org ) was developed based on women's views, values, and knowledge regarding risk-stratified breast cancer screening. This study aims to evaluate the impact of the decision aid on women's knowledge, risk perception, acceptance of risk assessment and change of screening frequency, and decision-making. Here we report the results of a pre and post-survey in which women who are clients of BreastScreen Victoria were invited to complete an online questionnaire before and after viewing the decision aid. 3200 potential participants were invited, 242 responded with 127 participants completing both surveys. After reviewing the decision aid there was a significant change in knowledge, acceptance of risk-stratified breast cancer screening and of decreased frequency screening for lower risk. High levels of acceptance of risk stratification, genetic testing and broad support for tailored screening persisted pre and post review. The DEFINE decision aid has a positive impact on acceptance of lower frequency screening, a major barrier to the success of a risk-stratified program and may contribute to facilitating change to the population breast screening program in Australia., (© 2023. Springer Nature Limited.)
- Published
- 2023
- Full Text
- View/download PDF
24. Contrast enhanced mammography in breast cancer surveillance.
- Author
-
Elder K, Matheson J, Nickson C, Box G, Ellis J, Mou A, Shadbolt C, Park A, Tay J, Rose A, and Mann GB
- Subjects
- Female, Humans, Retrospective Studies, Sensitivity and Specificity, Early Detection of Cancer methods, Australia epidemiology, Mammography methods, Breast pathology, Contrast Media, Breast Neoplasms diagnostic imaging, Breast Neoplasms epidemiology, Carcinoma, Intraductal, Noninfiltrating diagnostic imaging, Carcinoma, Intraductal, Noninfiltrating epidemiology
- Abstract
Purpose: Mammography (MG) is the standard imaging in surveillance of women with a personal history of breast cancer or DCIS (PHBC), supplemented with ultrasound. Contrast Enhanced Mammography (CEM) has higher sensitivity than MG and US. We report the performance of CEM compared with MG ± US., Methods: A retrospective study of patients undergoing their first surveillance CEM in an Australian hospital setting between June 2006 and October 2020. Cases where a patient was recalled for assessment were identified, recording radiology, pathology and treatment details. Blinded re-reading of recalled cases was performed to determine the contribution of contrast. Use of surveillance US across the board was assessed for the period., Results: 73/1191 (6.1%) patients were recalled. 35 (48%) were true positives (TP), with 26 invasive cancers and 9 cases of DCIS, while 38 (52%) were false positive (FP) with a positive predictive value (PPV) 47.9%. 32/73 were recalled due to MG findings, while 41/73 were only recalled due to Contrast. 14/73 had 'minimal signs' with a lesion identifiable on MG with knowledge of the contrast finding, while 27/73 were visible only with contrast. 41% (17/41) recalled due to contrast were TP. Contrast-only TPs were found with low and high mammographic density (MD). Screening breast US reduced by 55% in the year after CEM was implemented., Conclusion: Compared to MG, CEM as a single surveillance modality for those with PHBC has higher sensitivity and comparable specificity, identifying additional malignant lesions that are clinically significant. Investigation of interval cancer and subsequent round outcomes is warranted., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
25. Universal genetic testing for women with newly diagnosed breast cancer in the context of multidisciplinary team care.
- Author
-
De Silva DL, Stafford L, Skandarajah AR, Sinclair M, Devereux L, Hogg K, Kentwell M, Park A, Lal L, Zethoven M, Jayawardana MW, Chan F, Butow PN, James PA, Mann GB, Campbell IG, and Lindeman GJ
- Subjects
- Humans, Female, Prospective Studies, Genetic Predisposition to Disease, Genetic Testing, Patient Care Team, Breast Neoplasms diagnosis, Breast Neoplasms genetics
- Abstract
Objective: To determine the feasibility of universal genetic testing of women with newly diagnosed breast cancer, to estimate the incidence of pathogenic gene variants and their impact on patient management, and to evaluate patient and clinician acceptance of universal testing., Design, Setting, Participants: Prospective study of women with invasive or high grade in situ breast cancer and unknown germline status discussed at the Parkville Breast Service (Melbourne) multidisciplinary team meeting. Women were recruited to the pilot (12 June 2020 - 22 March 2021) and expansion phases (17 October 2021 - 8 November 2022) of the Mutational Assessment of newly diagnosed breast cancer using Germline and tumour genomICs (MAGIC) study., Main Outcome Measures: Germline testing by DNA sequencing, filtered for nineteen hereditary breast and ovarian cancer genes that could be classified as actionable; only pathogenic variants were reported. Surveys before and after genetic testing assessed pilot phase participants' perceptions of genetic testing, and psychological distress and cancer-specific worry. A separate survey assessed clinicians' views on universal testing., Results: Pathogenic germline variants were identified in 31 of 474 expanded study phase participants (6.5%), including 28 of 429 women with invasive breast cancer (6.5%). Eighteen of the 31 did not meet current genetic testing eligibility guidelines (probability of a germline pathogenic variant ≥ 10%, based on CanRisk, or Manchester score ≥ 15). Clinical management was changed for 24 of 31 women after identification of a pathogenic variant. Including 68 further women who underwent genetic testing outside the study, 44 of 542 women carried pathogenic variants (8.1%). Acceptance of universal testing was high among both patients (90 of 103, 87%) and clinicians; no decision regret or adverse impact on psychological distress or cancer-specific worry were reported., Conclusion: Universal genetic testing following the diagnosis of breast cancer detects clinically significant germline pathogenic variants that might otherwise be missed because of testing guidelines. Routine testing and reporting of pathogenic variants is feasible and acceptable for both patients and clinicians., (© 2023 The Authors. Medical Journal of Australia published by John Wiley & Sons Australia, Ltd on behalf of AMPCo Pty Ltd.)
- Published
- 2023
- Full Text
- View/download PDF
26. A modelled evaluation of the impact of COVID-19 on breast, bowel, and cervical cancer screening programmes in Australia.
- Author
-
Nickson C, Smith MA, Feletto E, Velentzis LS, Broun K, Deij S, Grogan P, Hall M, He E, St John DJ, Lew JB, Procopio P, Simms KT, Worthington J, Mann GB, and Canfell K
- Subjects
- Female, Humans, Early Detection of Cancer, Australia epidemiology, Uterine Cervical Neoplasms diagnosis, Uterine Cervical Neoplasms epidemiology, Uterine Cervical Neoplasms prevention & control, COVID-19 diagnosis, COVID-19 epidemiology, Breast Neoplasms diagnosis, Breast Neoplasms epidemiology, Breast Neoplasms prevention & control, Colorectal Neoplasms diagnosis, Colorectal Neoplasms epidemiology, Colorectal Neoplasms prevention & control
- Abstract
Australia introduced COVID-19 infection prevention and control measures in early 2020. To help prepare health services, the Australian Government Department of Health commissioned a modelled evaluation of the impact of disruptions to population breast, bowel, and cervical cancer screening programmes on cancer outcomes and cancer services. We used the Policy1 modelling platforms to predict outcomes for potential disruptions to cancer screening participation, covering periods of 3, 6, 9, and 12 mo. We estimated missed screens, clinical outcomes (cancer incidence, tumour staging), and various diagnostic service impacts. We found that a 12-mo screening disruption would reduce breast cancer diagnoses (9.3% population-level reduction over 2020-2021) and colorectal cancer (up to 12.1% reduction over 2020-21), and increase cervical cancer diagnoses (up to 3.6% over 2020-2022), with upstaging expected for these cancer types (2, 1.4, and 6.8% for breast, cervical, and colorectal cancers, respectively). Findings for 6-12-mo disruption scenarios illustrate that maintaining screening participation is critical to preventing an increase in the burden of cancer at a population level. We provide programme-specific insights into which outcomes are expected to change, when changes are likely to become apparent, and likely downstream impacts. This evaluation provided evidence to guide decision-making for screening programmes and emphasises the ongoing benefits of maintaining screening in the face of potential future disruptions., Competing Interests: CN, EF, LV, KB, SD, PG, MH, EH, JL, PP, KS, JW, KC No competing interests declared, MS reports salary support via fellowship grants from the NHMRC of Australia and Cancer Institute NSW and contracts paid to her institution (the Daffodil Centre) with the Commonwealth Department of Health (Australia) and National Screening Unit (New Zealand), DS Receives salary support from National Health Medical Research Council Investigator grant (APP1194784), GM is a PI of an investigator-initiated trial of cervical screening, (Compass;ACTRN12613001207707 and NCT02328872) run by the Australian Centre for the Prevention of Cervical Cancer, which is a government-funded not-for-profit charity; the Australian Centre for the Prevention of Cervical Cancer has received equipment and a funding contribution from Roche Molecular Diagnostics. KC is also co-PI on a major investigator-initiated implementation program Elimination of Cervical Cancer in the Western Pacific (ECCWP) which will receive support from the Minderoo Foundation, the Frazer Family Foundation and equipment donations from Cepheid Inc Neither KC nor her institution on her behalf have received direct funding from industry for any project. KC receives salary support from a National Health and Medical Research Council (NHMRC) of Australia fellowship grant, (© 2023, Nickson et al.)
- Published
- 2023
- Full Text
- View/download PDF
27. Breast Cancer Risk Assessment Tools for Stratifying Women into Risk Groups: A Systematic Review.
- Author
-
Velentzis LS, Freeman V, Campbell D, Hughes S, Luo Q, Steinberg J, Egger S, Mann GB, and Nickson C
- Abstract
Background: The benefits and harms of breast screening may be better balanced through a risk-stratified approach. We conducted a systematic review assessing the accuracy of questionnaire-based risk assessment tools for this purpose., Methods: Population: asymptomatic women aged ≥40 years; Intervention: questionnaire-based risk assessment tool (incorporating breast density and polygenic risk where available); Comparison: different tool applied to the same population; Primary outcome: breast cancer incidence; Scope: external validation studies identified from databases including Medline and Embase (period 1 January 2008-20 July 2021). We assessed calibration (goodness-of-fit) between expected and observed cancers and compared observed cancer rates by risk group. Risk of bias was assessed with PROBAST., Results: Of 5124 records, 13 were included examining 11 tools across 15 cohorts. The Gail tool was most represented ( n = 11), followed by Tyrer-Cuzick ( n = 5), BRCAPRO and iCARE-Lit ( n = 3). No tool was consistently well-calibrated across multiple studies and breast density or polygenic risk scores did not improve calibration. Most tools identified a risk group with higher rates of observed cancers, but few tools identified lower-risk groups across different settings. All tools demonstrated a high risk of bias., Conclusion: Some risk tools can identify groups of women at higher or lower breast cancer risk, but this is highly dependent on the setting and population.
- Published
- 2023
- Full Text
- View/download PDF
28. A Novel Biosignature Identifies Patients With DCIS With High Risk of Local Recurrence After Breast Conserving Surgery and Radiation Therapy.
- Author
-
Vicini FA, Mann GB, Shah C, Weinmann S, Leo MC, Whitworth P, Rabinovitch R, Torres MA, Margenthaler JA, Dabbs D, Savala J, Shivers SC, Mittal K, Wärnberg F, and Bremer T
- Subjects
- Humans, Female, Mastectomy, Segmental methods, Neoplasm Recurrence, Local pathology, Proportional Hazards Models, Risk Factors, Carcinoma, Intraductal, Noninfiltrating radiotherapy, Carcinoma, Intraductal, Noninfiltrating surgery, Carcinoma, Intraductal, Noninfiltrating pathology, Breast Neoplasms radiotherapy, Breast Neoplasms surgery
- Abstract
Purpose: There is an unmet need to identify women diagnosed with ductal carcinoma in situ (DCIS) with a low risk of in-breast recurrence (IBR) after breast conserving surgery (BCS), which could omit radiation therapy (RT), and also to identify those with elevated IBR risk remaining after BCS plus RT. We evaluated a novel biosignature for a residual risk subtype (RRt) to help identify patients with elevated IBR risk after BCS plus RT., Methods and Materials: Women with DCIS treated with BCS with or without RT at centers in the US, Australia, and Sweden (n = 926) were evaluated. Patients were classified into 3 biosignature risk groups using the decision score (DS) and the RRt category: (1) Low Risk (DS ≤2.8 without RRt), (2) Elevated Risk (DS >2.8 without RRt), and (3) Residual Risk (DS >2.8 with RRt). Total and invasive IBR rates were assessed by risk group and treatment., Results: In patients at low risk, there was no significant difference in IBR rates with or without RT (total, P = .8; invasive IBR, P = .7), and there were low overall 10-year rates (total, 5.1%; invasive, 2.7%). In patients with elevated risk, IBR rates were decreased with RT (total: hazard ratio [HR], 0.25; P < .001; invasive: HR, 0.28; P = .005); 10-year rates were 20.6% versus 4.9% (total) and 10.9% versus 3.1% (invasive). In patients with residual risk, although IBR rates decreased with RT after BCS (total: HR, 0.21; P < .001; invasive: HR, 0.29; P = .028), IBR rates remained significantly higher after RT compared with patients with elevated risk (HR, 2.5; 95% CI, 1.2-5.4; P = .018), with 10-year rates of 42.1% versus 14.7% (total) and 18.3% versus 6.5% (invasive)., Conclusions: The novel biosignature identified patients with 3 distinct risk profiles: Low Risk patients with a low recurrence risk with or without adjuvant RT, Elevated Risk patients with excellent outcomes after BCS plus RT, and Residual Risk patients with an elevated recurrence risk remaining after BCS plus RT, warranting potential intensified or alternative treatment approaches., (Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
29. Impact of the EndoPredict genomic assay on treatment decisions for oestrogen receptor-positive early breast cancer patients: benefits of physician selective testing.
- Author
-
Dinh P, Graham JD, Elder EN, Kabir M, Doan TB, French J, Meybodi F, Hui R, Wilcken NR, Harnett PR, Hsu J, Stuart KE, Wang T, Ahern V, Brennan M, Fox SB, Dear RF, Lim E, White M, Mann GB, and Pathmanathan N
- Subjects
- Chemotherapy, Adjuvant, Cohort Studies, Female, Genomics, Humans, Prognosis, Receptor, ErbB-2 genetics, Receptors, Estrogen genetics, Breast Neoplasms diagnosis, Breast Neoplasms drug therapy, Breast Neoplasms genetics, Physicians
- Abstract
Purpose: Genomic tests improve accuracy of risk prediction for early breast cancers but these are expensive. This study evaluated the clinical utility of EndoPredict®, in terms of impact on adjuvant therapy recommendations and identification of parameters to guide selective application., Methods: Patients with ER-positive, HER2-negative, and early-stage invasive breast cancer were tested with EndoPredict®. Two cohorts were recruited: one consecutively and another at clinical team discretion. Systemic treatment recommendations were recorded before and after EndoPredict® results were revealed to the multidisciplinary team., Results: 233 patients were recruited across five sites: 123 consecutive and 110 at clinical team discretion. In the consecutive cohort 50.6% (62/123) cases were classified high risk of recurrence by EndoPredict®, compared with 62.7% (69/110) in the selective cohort. A change in treatment recommendation was significantly more likely (p < 0.0001) in the selective cohort (43/110, 39.1%) compared to the consecutive group (11/123, 8.9%). The strongest driver of selective recruitment was intermediate grade histology, whilst logistic regression modelling demonstrated that nodal status (p < 0.001), proliferative rate (p = 0.001), and progesterone receptor positivity (p < 0.001) were the strongest discriminators of risk., Conclusion: Whilst molecular risk can be predicted by traditional variables in a high proportion of cases, EndoPredict® had a greater impact on treatment decisions in those cases selected for testing at team discretion. This is indicative of the robust ability of the clinical team to identify cases most likely to benefit from testing, underscoring the value of genomic tests in the oncologists' tool kit., (© 2021. Crown.)
- Published
- 2022
- Full Text
- View/download PDF
30. Development and pilot testing of an online decision aid for women considering risk-stratified breast screening.
- Author
-
Lippey J, Keogh L, Campbell I, Mann GB, and Forrest L
- Published
- 2022
- Full Text
- View/download PDF
31. Prognostic Risk Assessment and Prediction of Radiotherapy Benefit for Women with Ductal Carcinoma In Situ (DCIS) of the Breast, in a Randomized Clinical Trial (SweDCIS).
- Author
-
Wärnberg F, Karlsson P, Holmberg E, Sandelin K, Whitworth PW, Savala J, Barry T, Leesman G, Linke SP, Shivers SC, Vicini F, Shah C, Weinmann S, Mann GB, and Bremer T
- Abstract
Prediction of radiotherapy (RT) benefit after breast-conserving surgery (BCS) for DCIS is crucial. The aim was to validate a biosignature, DCISionRT
® , in the SweDCIS randomized trial. Women were randomly assigned to RT or not after BCS, between 1987 and 2000. Tumor blocks were collected, and slides were sent to PreludeDxTM for testing. In 504 women with complete data and negative margins, DCISionRT divided 52% women into Elevated (DS > 3) and 48% in Low (DS ≤ 3) Risk groups. In the Elevated Risk group, RT significantly decreased relative 10-year ipsilateral total recurrence (TotBE) and 10-year ipsilateral invasive recurrence (InvBE) rates, HR 0.32 and HR 0.24, with absolute decreases of 15.5% and 9.3%. In the Low Risk group, there were no significant risk differences observed with radiotherapy. Using a cutoff of DS > 3.0, the test was not predictive for RT benefit ( p = 0.093); however, above DS > 2.8 RT benefit was greater for InvBE (interaction p = 0.038). Recurrences at 10 years without radiotherapy increased significantly per 5 DS units (TotBE HR:1.5 and InvBE HR:1.5). Continuous DS was prognostic for TotBE risk although categorical DS did not reach significance. Absolute 10-year TotBE and InvBE risks appear sufficiently different to indicate that DCISionRT can aid physicians in selecting individualized adjuvant DCIS treatment strategies. Further analyses are planned in combined cohorts to increase statistical power.- Published
- 2021
- Full Text
- View/download PDF
32. POSNOC-POsitive Sentinel NOde: adjuvant therapy alone versus adjuvant therapy plus Clearance or axillary radiotherapy: a randomised controlled trial of axillary treatment in women with early-stage breast cancer who have metastases in one or two sentinel nodes.
- Author
-
Goyal A, Mann GB, Fallowfield L, Duley L, Reed M, Dodwell D, Coleman RE, Fakis A, Newcombe R, Jenkins V, Whitham D, Childs M, Whynes D, Keeley V, Ellis I, Fairbrother P, Sadiq S, Monson K, Montgomery A, Tan W, Vale L, Homer T, Badger H, Haines RH, Lewis M, Megias D, Nabi Z, Singh P, Caraman A, and Miles E
- Subjects
- Axilla pathology, Female, Humans, Lymph Node Excision, Lymphatic Metastasis, Mastectomy, Quality of Life, Radiotherapy, Adjuvant, Breast Neoplasms pathology, Breast Neoplasms radiotherapy
- Abstract
Introduction: ACOSOG-Z0011(Z11) trial showed that axillary node clearance (ANC) may be omitted in women with ≤2 positive nodes undergoing breast conserving surgery (BCS) and whole breast radiotherapy (RT). A confirmatory study is needed to clarify the role of axillary treatment in women with ≤2 macrometastases undergoing BCS and groups that were not included in Z11 for example, mastectomy and those with microscopic extranodal invasion. The primary objective of POsitive Sentinel NOde: adjuvant therapy alone versus adjuvant therapy plus Clearance or axillary radiotherapy (POSNOC) is to evaluate whether for women with breast cancer and 1 or 2 macrometastases, adjuvant therapy alone is non-inferior to adjuvant therapy plus axillary treatment, in terms of 5-year axillary recurrence., Methods and Analysis: POSNOC is a pragmatic, multicentre, non-inferiority, international trial with participants randomised in a 1:1 ratio. Women are eligible if they have T1/T2, unifocal or multifocal invasive breast cancer, and 1 or 2 macrometastases at sentinel node biopsy, with or without extranodal extension. In the intervention group women receive adjuvant therapy alone, in the standard care group they receive ANC or axillary RT. In both groups women receive adjuvant therapy, according to local guidelines. This includes systemic therapy and, if indicated, RT to breast or chest wall. The UK Radiotherapy Trials Quality Assurance Group manages the in-built radiotherapy quality assurance programme. Primary endpoint is 5-year axillary recurrence. Secondary outcomes are arm morbidity assessed by Lymphoedema and Breast Cancer Questionnaire and QuickDASH questionnaires; quality of life and anxiety as assessed with FACT B+4 and State/Trait Anxiety Inventory questionnaires, respectively; other oncological outcomes; economic evaluation using EQ-5D-5L. Target sample size is 1900. Primary analysis is per protocol. Recruitment started on 1 August 2014 and as of 9 June 2021, 1866 participants have been randomised., Ethics and Dissemination: Protocol was approved by the National Research Ethics Service Committee East Midlands-Nottingham 2 (REC reference: 13/EM/0459). Results will be submitted for publication in peer-reviewed journals., Trial Registration Number: ISRCTN54765244; NCT0240168Cite Now., Competing Interests: Competing interests: LV was a member of the NIHR Health Technology Assessment Programme, Clinical Trials and Evaluation Panel from 2014 to 2018., (© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ.)
- Published
- 2021
- Full Text
- View/download PDF
33. Factors involved in treatment decision making for women diagnosed with ductal carcinoma in situ: A qualitative study.
- Author
-
Hatton A, Heriot N, Zalcberg J, Ayton D, Evans J, Roder D, Chua BH, Hersch J, Lippey J, Fox J, Saunders C, Mann GB, Synnot J, and Bell RJ
- Subjects
- Australia, Decision Making, Female, Humans, Mastectomy, Breast Neoplasms diagnosis, Breast Neoplasms therapy, Carcinoma, Intraductal, Noninfiltrating surgery, Carcinoma, Intraductal, Noninfiltrating therapy
- Abstract
Whilst some of the diversity in management of women with ductal carcinoma in situ (DCIS) may be explained by tumour characteristics, the role of patient preference and the factors underlying those preferences have been less frequently examined. We have used a descriptive qualitative study to explore treatment decisions for a group of Australian women diagnosed with DCIS through mammographic screening. Semi-structured telephone interviews were performed with 16 women diagnosed with DCIS between January 2012 and December 2018, recruited through the LifePool dataset (a subset of BreastScreen participants who have agreed to participate in research). Content analysis using deductive coding identified three themes: participants did not have a clear understanding of their diagnosis or prognosis; reported involvement in decision making about management varied; specific factors including the psychosexual impact of mastectomy and perceptions of radiotherapy, could act as barriers or facilitators to specific decisions about treatment. The treatment the women received was not simply determined by the characteristics of their disease. Interaction with the managing clinician was pivotal, however many other factors played a part in individual decisions. Recognising that decisions are not purely a function of disease characteristics is important for both women with DCIS and the clinicians who care for them., (Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
34. Universal genetic testing of patients with newly diagnosed breast cancer - ready for prime time?
- Author
-
De Silva DL, James PA, Mann GB, and Lindeman GJ
- Subjects
- Early Detection of Cancer economics, Female, Genes, BRCA1, Genes, BRCA2, Genetic Predisposition to Disease, Germ-Line Mutation, Health Care Costs, Humans, Breast Neoplasms diagnosis, Breast Neoplasms genetics, Early Detection of Cancer methods, Genetic Testing economics
- Published
- 2021
- Full Text
- View/download PDF
35. Multicentre evaluation of magnetic technology for localisation of non-palpable breast lesions and targeted axillary nodes.
- Author
-
McCamley C, Ruyssers N, To H, Tsao S, Keane H, Poliness C, Mehta K, Rose A, Baker C, and Mann GB
- Subjects
- Axilla, Female, Humans, Lymph Nodes, Magnetic Phenomena, Prospective Studies, Technology, Breast diagnostic imaging, Breast surgery, Breast Neoplasms surgery
- Abstract
Background: Magseed technology is a recently introduced localisation technique for impalpable breast lesions with possible advantages over traditional techniques. These include improved theatre logistics, flexibility in incision placement and improved patient experience. This multicentre study evaluates the experience of introducing Magseed technology into routine surgical practice., Methods: A prospective multicentre study of Magseed localised procedures was performed. Insertion data were recorded by the radiologist including lesion characteristics and Magseed insertion accuracy. The surgical team recorded time from insertion to operation, operating time and surgical satisfaction. Pathology results were reviewed for specimen weight and margins., Results: Between February 2019 and June 2020, 100 patients were enrolled. Magseed localised procedures included 18 excisional biopsies, 23 wide local excisions (WLE), 50 WLE with axillary surgery and four cases of Magseed localised breast WLE with Magseed localised axillary surgery. There were three therapeutic mammoplasties and two cases of Magseed localised targeted axillary node dissection alone. A total of 90% of Magseeds were radiologically placed within 5 mm of the target lesion/node. Time between incision and specimen removal was 17 min (range 6-40 min). All breast and axillary Magseeds were successfully identified and retrieved during surgery. The target lesion was identified in the specimen in all cases. A total of 10% of cases required further surgery for pathologically positive margins. Overall, surgeons reported that Magseed localisation was "easy" or "very easy" in 77% of cases., Conclusion: Magseed is a reliable, safe and accurate surgical technique that provides logistical advantages and flexibility of surgical approach. The method was well-accepted by all users., (© 2021 Royal Australasian College of Surgeons.)
- Published
- 2021
- Full Text
- View/download PDF
36. Colorimetric histology using plasmonically active microscope slides.
- Author
-
Balaur E, O' Toole S, Spurling AJ, Mann GB, Yeo B, Harvey K, Sadatnajafi C, Hanssen E, Orian J, Nugent KA, Parker BS, and Abbey B
- Subjects
- Animals, Breast Neoplasms pathology, Carcinoma, Intraductal, Noninfiltrating pathology, Cohort Studies, Disease Models, Animal, Female, Humans, Ki-67 Antigen analysis, Mice, Mice, Inbred C57BL, Colorimetry instrumentation, Colorimetry methods, Histological Techniques instrumentation, Microscopy instrumentation
- Abstract
The human eye can distinguish as many as 10,000 different colours but is far less sensitive to variations in intensity
1 , meaning that colour is highly desirable when interpreting images. However, most biological samples are essentially transparent, and nearly invisible when viewed using a standard optical microscope2 . It is therefore highly desirable to be able to produce coloured images without needing to add any stains or dyes, which can alter the sample properties. Here we demonstrate that colorimetric histology images can be generated using full-sized plasmonically active microscope slides. These slides translate subtle changes in the dielectric constant into striking colour contrast when samples are placed upon them. We demonstrate the biomedical potential of this technique, which we term histoplasmonics, by distinguishing neoplastic cells from normal breast epithelium during the earliest stages of tumorigenesis in the mouse MMTV-PyMT mammary tumour model. We then apply this method to human diagnostic tissue and validate its utility in distinguishing normal epithelium, usual ductal hyperplasia, and early-stage breast cancer (ductal carcinoma in situ). The colorimetric output of the image pixels is compared to conventional histopathology. The results we report here support the hypothesis that histoplasmonics can be used as a novel alternative or adjunct to general staining. The widespread availability of this technique and its incorporation into standard laboratory workflows may prove transformative for applications extending well beyond tissue diagnostics. This work also highlights opportunities for improvements to digital pathology that have yet to be explored., (© 2021. The Author(s), under exclusive licence to Springer Nature Limited.)- Published
- 2021
- Full Text
- View/download PDF
37. An inverse stage-shift model to estimate the excess mortality and health economic impact of delayed access to cancer services due to the COVID-19 pandemic.
- Author
-
Degeling K, Baxter NN, Emery J, Jenkins MA, Franchini F, Gibbs P, Mann GB, McArthur G, Solomon BJ, and IJzerman MJ
- Subjects
- Australia epidemiology, Female, Humans, Pandemics, SARS-CoV-2, Breast Neoplasms mortality, COVID-19, Colorectal Neoplasms mortality, Lung Neoplasms mortality
- Abstract
Aim: Decreased cancer incidence and reported changes to clinical management indicate that the COVID-19 pandemic has delayed cancer diagnosis and treatment. This study aimed to develop and apply a flexible model to estimate the impact of delayed diagnosis and treatment on survival outcomes and healthcare costs based on a shift in the disease stage at treatment initiation., Methods: A model was developed and made publicly available to estimate population-level health economic outcomes by extrapolating and weighing stage-specific outcomes by the distribution of stages at treatment initiation. It was applied to estimate the impact of 3- and 6-month delays based on Australian data for stage I breast cancer, colorectal cancer, and lung cancer patients, and for T1 melanoma. Two approaches were explored to estimate stage shifts following a delay: (a) based on the relation between time to treatment initiation and overall survival (breast, colorectal, and lung cancer), and (b) based on the tumor growth rate (melanoma)., Results: Using a conservative once-off 3-month delay and considering only shifts from stage I/T1 to stage II/T2, 88 excess deaths and $12 million excess healthcare costs were predicted in Australia over 5 years for all patients diagnosed in 2020. For a 6-month delay, excess mortality and healthcare costs were 349 deaths and $46 million over 5 years., Conclusions: The health and economic impacts of delays in treatment initiation cause an imminent policy concern. More accurate individual patient data on shifts in stage of disease during and after the COVID-19 pandemic are critical for further analyses., (© 2021 John Wiley & Sons Australia, Ltd.)
- Published
- 2021
- Full Text
- View/download PDF
38. Moving beyond the stage: how characteristics at diagnosis dictate treatment and treatment-related quality of life year losses for women with early stage invasive breast cancer.
- Author
-
Saxby K, Nickson C, Mann GB, Park A, Bromley H, Velentzis L, Procopio P, Canfell K, and Petrie D
- Subjects
- Aged, Antineoplastic Agents administration & dosage, Antineoplastic Agents adverse effects, Breast Neoplasms pathology, Breast Neoplasms therapy, Early Detection of Cancer methods, Female, Humans, Mastectomy adverse effects, Mastectomy methods, Middle Aged, Neoplasm Staging, Prognosis, Breast Neoplasms diagnosis, Mass Screening methods, Quality of Life, Quality-Adjusted Life Years
- Abstract
Background :Although evaluations of breast cancer screening programs frequently estimate quality-adjusted life-year (QALY) losses by stage, other breast cancer characteristics influence treatment and vary by mode of detection - i.e. whether the cancer is detected through screening (screen-detected), between screening rounds (interval-detected) or outside screening (community-detected). Here, we estimate the association between early-stage invasive breast cancer (ESIBC) characteristics and treatment-related QALY losses. Methods :Using clinicopathological and treatment information from 675 women managed for ESIBC, we estimated the average five-year treatment-related QALY loss by detection group. We then used regression analysis to estimate the extent to which known cancer characteristics and the detection mode, are associated with treatment and treatment-related QALY losses. Results :Community-detected cancers had the largest QALY loss (0.76 QALYs [95% CI 0.73;0.80]), followed by interval-detected cancers (0.75 QALYs [95% CI 0.68;0.82]) and screen-detected cancers (0.69 QALYs [95%CI 0.67;0.71]). Adverse prognostic factors more common in community-detected and interval-detected breast cancers (large tumours, lymph node involvement, high grade) were largely associated with QALY losses from mastectomies and chemotherapy. Receptor-positive subtypes, more common in screen-detected cancers, were associated with QALY losses related to endocrine therapy. Conclusions :The associations between ESIBC characteristics and treatment-related QALY losses should be considered when evaluating breast cancer screening and treatment strategies.
- Published
- 2021
- Full Text
- View/download PDF
39. Feasibility of Enhancing Parenting in Cancer, a psychoeducational intervention for communicating with children about parental cancer.
- Author
-
Stafford L, Sinclair M, Rauch P, Turner J, Mann GB, Newman L, Wakefield CE, Gilham L, Mason K, Cannell J, Little R, and Schofield P
- Subjects
- Child, Feasibility Studies, Humans, Parent-Child Relations, Parents, Neoplasms therapy, Parenting
- Published
- 2021
- Full Text
- View/download PDF
40. A single-cell RNA expression atlas of normal, preneoplastic and tumorigenic states in the human breast.
- Author
-
Pal B, Chen Y, Vaillant F, Capaldo BD, Joyce R, Song X, Bryant VL, Penington JS, Di Stefano L, Tubau Ribera N, Wilcox S, Mann GB, Papenfuss AT, Lindeman GJ, Smyth GK, and Visvader JE
- Subjects
- Breast Neoplasms classification, Breast Neoplasms genetics, Breast Neoplasms pathology, CD8-Positive T-Lymphocytes metabolism, Carcinogenesis genetics, Carcinogenesis metabolism, Carcinogenesis pathology, Female, Gene Expression Profiling, Humans, Mammary Glands, Human cytology, Mammary Glands, Human pathology, RNA-Seq, Tumor Microenvironment, Breast Neoplasms metabolism, Gene Expression Regulation, Neoplastic, Genetic Heterogeneity, Mammary Glands, Human metabolism, Single-Cell Analysis
- Abstract
To examine global changes in breast heterogeneity across different states, we determined the single-cell transcriptomes of > 340,000 cells encompassing normal breast, preneoplastic BRCA1
+/- tissue, the major breast cancer subtypes, and pairs of tumors and involved lymph nodes. Elucidation of the normal breast microenvironment revealed striking changes in the stroma of post-menopausal women. Single-cell profiling of 34 treatment-naive primary tumors, including estrogen receptor (ER)+ , HER2+ , and triple-negative breast cancers, revealed comparable diversity among cancer cells and a discrete subset of cycling cells. The transcriptomes of preneoplastic BRCA1+/- tissue versus tumors highlighted global changes in the immune microenvironment. Within the tumor immune landscape, proliferative CD8+ T cells characterized triple-negative and HER2+ cancers but not ER+ tumors, while all subtypes comprised cycling tumor-associated macrophages, thus invoking potentially different immunotherapy targets. Copy number analysis of paired ER+ tumors and lymph nodes indicated seeding by genetically distinct clones or mass migration of primary tumor cells into axillary lymph nodes. This large-scale integration of patient samples provides a high-resolution map of cell diversity in normal and cancerous human breast., (© 2021 The Authors. Published under the terms of the CC BY NC ND 4.0 license.)- Published
- 2021
- Full Text
- View/download PDF
41. Breast MRI in DCIS size estimation, breast-conserving surgery and oncoplastic breast surgery.
- Author
-
Bartram A, Gilbert F, Thompson A, Mann GB, and Agrawal A
- Subjects
- Female, Humans, Magnetic Resonance Imaging, Mastectomy statistics & numerical data, Mastectomy, Segmental statistics & numerical data, Reoperation statistics & numerical data, Retrospective Studies, Treatment Outcome, Breast Neoplasms diagnostic imaging, Breast Neoplasms surgery, Carcinoma, Ductal, Breast diagnostic imaging, Carcinoma, Ductal, Breast surgery, Carcinoma, Intraductal, Noninfiltrating diagnostic imaging, Carcinoma, Intraductal, Noninfiltrating surgery
- Abstract
The impact of MRI on improving surgical outcomes in DCIS is debated. Here, we explore the utility of MRI in the investigation and management of DCIS in three key areas. Firstly, we highlight that MRI is likely to be a more accurate predictor of actual tumour size than conventional imaging. Secondly, we examine mastectomy rates and reoperation rates across the literature and suggest that surgical outcomes do not differ between pre-operative MRI and conventional imaging groups, despite improved size estimation on MRI. Finally, we examine the rapidly developing field of oncoplastic breast surgery and highlight a paucity of data in determining the usefulness of pre-operative MRI in this field, despite this being an oncologically safe alternative with improved patient outcomes and satisfaction., (Crown Copyright © 2021. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
42. The financial impact of a breast cancer detected within and outside of screening: lessons from the Australian Lifepool cohort.
- Author
-
Saxby K, Nickson C, Mann GB, Velentzis L, Bromley HL, Procopio P, Canfell K, and Petrie D
- Subjects
- Adult, Aged, Australia epidemiology, Breast Neoplasms epidemiology, Carcinoma, Intraductal, Noninfiltrating epidemiology, Cohort Studies, Female, Health Services economics, Humans, Middle Aged, Neoplasm Staging, Registries, Breast Neoplasms diagnosis, Carcinoma, Intraductal, Noninfiltrating diagnosis, Early Detection of Cancer economics, Health Care Costs statistics & numerical data, Health Services statistics & numerical data, Mammography economics, Mass Screening economics
- Abstract
Objective: To determine the government and out-of-pocket community costs (out-of-hospital medical services and prescription medicines) associated with screen-detected and community-detected cancers (i.e. cancers detected outside of Australia's organised screening program [BreastScreen])., Methods: We analyse administrative data on government-subsidised medical services and prescription medicines for 568 Victorian women diagnosed with breast cancer or ductal carcinoma in situ (DCIS). Using multivariable regression analysis, we estimate the government and out-of-pocket community costs incurred in the three years after diagnosis for screen-detected cancers and community-detected cancers. Additionally, we estimate the government costs associated with diagnosis within and outside of BreastScreen., Results: Average government costs for breast cancer diagnosis were similar within and outside of BreastScreen [$808 (lower limit 676; upper limit 940) vs $837 (95%CI 671; 1,003) respectively]; however, women with community-detected cancers incurred an additional $254 (95%CI 175; 332) out-of-pocket. Controlling for differences in known cancer characteristics, compared to screen-detected cancers, community-detected breast cancers were associated with an additional $2,622 (95%CI 644; 4,776) in government expenditure in the three years following diagnosis. Adverse cancer characteristics that were more prevalent in community-detected cancers (high grade, lymph node involvement, HER2 positive receptor status) were associated with increased government and out-of-pocket costs., Conclusions: Community-detected breast cancers were associated with increased government and out-of-pocket costs. Implications for public health: These costs should be considered when evaluating current and alternative breast cancer screening strategies., (© 2020 The Authors.)
- Published
- 2020
- Full Text
- View/download PDF
43. Breast Cancer Survivor Symptoms: A Comparison of Physicians' Consultation Records and Nurse-Led Survivorship Care Plans.
- Author
-
Kozul C, Stafford L, Little R, Bousman C, Park A, Shanahan K, and Mann GB
- Subjects
- Adult, Aged, Aged, 80 and over, Australia, Breast Neoplasms physiopathology, Breast Neoplasms psychology, Female, Humans, Longitudinal Studies, Middle Aged, Practice Guidelines as Topic, Referral and Consultation statistics & numerical data, Retrospective Studies, Surveys and Questionnaires, Survivorship, Symptom Assessment statistics & numerical data, Young Adult, Cancer Survivors statistics & numerical data, Continuity of Patient Care statistics & numerical data, Nursing Staff, Hospital statistics & numerical data, Patient Care Planning statistics & numerical data, Physicians statistics & numerical data, Practice Patterns, Physicians' statistics & numerical data, Referral and Consultation standards, Symptom Assessment standards
- Abstract
Background: Survivorship care plans (SCPs) have been used to address ongoing health problems associated with the diagnosis and treatment of early-stage breast cancer., Objectives: The aim of this article was to determine whether nurse-led consultations using SCPs, as compared with a standard medical consultation, identify more side effects and supportive care needs and lead to appropriate referral patterns., Methods: The study audited 160 retrospective medical clinic and nursing SCP records in a sample of patients receiving treatment for early-stage breast cancer at a tertiary-level breast service in Australia., Findings: Breast care nurses (BCNs) undertaking SCPs at a nurse-led consultation were significantly more likely than physicians to record symptoms related to menopausal/hormonal therapy, psychosocial/mental health, lifestyle, bone health, and sexuality. BCNs were also significantly more likely to refer patients for concerns related to psychosocial/mental health, lifestyle, and sexuality.
- Published
- 2020
- Full Text
- View/download PDF
44. Outcomes of women at high familial risk for breast cancer: An 8-year single-center experience.
- Author
-
Lammert J, Skandarajah AR, Shackleton K, Calder P, Thomas S, Lindeman GJ, and Mann GB
- Subjects
- Adolescent, Adult, Aged, Female, Humans, Middle Aged, Prospective Studies, Retrospective Studies, Time Factors, Treatment Outcome, Young Adult, Breast Neoplasms epidemiology, Genetic Predisposition to Disease genetics
- Abstract
Objectives: The value of a high-risk surveillance program for mutation carriers and women at high familial breast cancer risk has not been extensively studied. A Breast and Ovarian Cancer Risk Management Clinic (BOCRMC) was established at the Royal Melbourne Hospital in 2010 to provide multimodality screening and risk management strategies for this group of women. The aims of this study were to evaluate the program and describe breast cancer diagnoses for BRCA1, BRCA2, and other germline mutation carriers as well as high-risk noncarriers attending the BOCRMC., Methods: Clinical data from mutation carriers and noncarriers with a ≥25% lifetime risk of developing breast cancer who attended between 2010 and 2018 were extracted from clinic records and compared. The pattern and mode of detection of cancer were determined., Results: A total of 206 mutation carriers and 305 noncarriers attended the BOCRMC and underwent screening on at least one occasion. Median age was 37 years. After a median follow-up of 34 months, 15 (seven invasive) breast cancers were identified in mutation carriers, with seven (six invasive) breast cancers identified in noncarriers. Of these, 20 (90.9%) were detected by annual screening, whereas two (9.1%) were detected as interval cancers (both in BRCA1 mutation carriers). Median size of the invasive breast cancers was 11 mm (range: 1.5-30 mm). The majority (76.9%) were axillary node negative. In women aged 25-49 years, the annualized cancer incidence was 1.6% in BRCA1, 1.4% in BRCA2 mutation carriers, and 0.5% in noncarriers. This compares to 0.06% annualized cancer incidence in the general Australian population., Conclusions: Screening was effective at detecting early-stage cancers. The incidence of events in young noncarriers was substantially higher than in the general population. This potentially justifies ongoing management through a specialty clinic, although further research to better personalize risk assessment in noncarriers is required., (© 2019 John Wiley & Sons Australia, Ltd.)
- Published
- 2020
- Full Text
- View/download PDF
45. The genetic architecture of breast papillary lesions as a predictor of progression to carcinoma.
- Author
-
Kader T, Elder K, Zethoven M, Semple T, Hill P, Goode DL, Thio N, Cheasley D, Rowley SM, Byrne DJ, Pang JM, Miligy IM, Green AR, Rakha EA, Fox SB, Mann GB, Campbell IG, and Gorringe KL
- Abstract
Intraductal papillomas (IDP) are challenging breast findings because of their variable risk of progression to malignancy. The molecular events driving IDP development and genomic features of malignant progression are poorly understood. In this study, genome-wide CNA and/or targeted mutation analysis was performed on 44 cases of IDP, of which 20 cases had coexisting ductal carcinoma in situ (DCIS), papillary DCIS or invasive ductal carcinoma (IDC). CNA were rare in pure IDP, but 69% carried an activating PIK3CA mutation. Among the synchronous IDP cases, 55% (11/20) were clonally related to the synchronous DCIS and/or IDC, only one of which had papillary histology. In contrast to pure IDP, PIK3CA mutations were absent from clonal cases. CNAs in any of chromosomes 1, 16 or 11 were significantly enriched in clonal IDP lesions compared to pure and non-clonal IDP. The observation that 55% of IDP are clonal to DCIS/IDC indicates that IDP can be a direct precursor for breast carcinoma, not limited to the papillary type. The absence of PIK3CA mutations and presence of CNAs in IDP could be used clinically to identify patients at high risk of progression to carcinoma., Competing Interests: Competing interestsThe authors declare no competing interests., (© The Author(s) 2020.)
- Published
- 2020
- Full Text
- View/download PDF
46. Window of opportunity treatment in breast cancer.
- Author
-
Chen J, Easwaralingam N, Warrier S, Ong A, Carson EK, Mak C, Snook K, Middleton K, Parker A, Palmieri C, Spillane A, Mann GB, Lim E, and Segara D
- Subjects
- Antineoplastic Agents therapeutic use, Antineoplastic Agents, Hormonal therapeutic use, Biomarkers, Tumor, Combined Modality Therapy, Evidence-Based Medicine, Female, Humans, Mastectomy, Neoadjuvant Therapy, Prognosis, Breast Neoplasms therapy
- Abstract
Window of opportunity therapies, which involve short-term administration of systemic therapy between cancer diagnosis and surgery, have raised significant interest in recent years as a mean of assessing the sensitivity of a patient's cancer to therapy prior to surgery. There is now compelling evidence that in patients with early stage hormone-receptor positive breast cancer, a 2-week preoperative treatment with standard hormone therapies in a preoperative window period provides important prognostic information, which in turn helps to aid decision-making regarding treatment options. Changes in short-term biomarker endpoints such as cell proliferation measured by Ki-67 can act as surrogate markers of long-term outcomes. Paired tissues obtained pre- and post-investigational treatment, without having to subject the patient to additional biopsies, can then be used to conduct translational research to investigate predictive biomarkers and pharmacodynamics. In this review, we will examine the utility and challenges of window of opportunities therapies in breast cancer in the current literature, and the current Australian and international trial landscape in this clinical space., (© 2019 Royal Australasian College of Surgeons.)
- Published
- 2020
- Full Text
- View/download PDF
47. Valuing preferences for treating screen detected ductal carcinoma in situ.
- Author
-
Bromley HL, Mann GB, Petrie D, Nickson C, Rea D, and Roberts TE
- Subjects
- Aged, Breast Neoplasms diagnostic imaging, Carcinoma, Intraductal, Noninfiltrating diagnostic imaging, Disease Management, Early Detection of Cancer, Female, Humans, Male, Mastectomy, Mastectomy, Segmental, Medical Overuse, Middle Aged, Patient Acceptance of Health Care, Radiotherapy, Adjuvant, Breast Neoplasms therapy, Carcinoma, Intraductal, Noninfiltrating therapy, Patient Preference, Quality of Life, Watchful Waiting
- Abstract
Background: Mammographic screening reduces breast cancer mortality but may lead to the overdiagnosis and overtreatment of low-risk breast cancers. Conservative management may reduce the potential harm of overtreatment, yet little is known about the impact upon quality of life., Objectives: To quantify women's preferences for managing low-risk screen detected ductal carcinoma in situ (DCIS), including the acceptability of active monitoring as an alternative treatment., Methods: Utilities (cardinal measures of quality of life) were elicited from 172 women using visual analogue scales (VASs), standard gambles, and the Euro-Qol-5D-5L questionnaire for seven health states describing treatments for low-risk DCIS. Sociodemographics and breast cancer history were examined as predictors of utility., Results: Both patients and non-patients valued active monitoring more favourably on average than conventional treatment. Utilities were lowest for DCIS treated with mastectomy (VAS: 0.454) or breast conserving surgery (BCS) with adjuvant radiotherapy (VAS: 0.575). The utility of active monitoring was comparable to BCS alone but was rated more favourably as progression risk was reduced from 40% to 10%. Disutility for active monitoring was likely driven by anxiety around progression, whereas conventional management impacted other dimensions of quality of life. The heterogeneity between individual preferences could not be explained by sociodemographic variables, suggesting that the factors influencing women's preferences are complex., Conclusions: Active monitoring of low-risk DCIS is likely to be an acceptable alternative for reducing the impact of overdiagnosis and overtreatment in terms of quality of life. Further research is required to determine subgroups more likely to opt for conservative management., (Copyright © 2019 Elsevier Ltd. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
48. Maternal breast cancer and communicating with children: A qualitative exploration of what resources mothers want and what health professionals provide.
- Author
-
Sinclair M, Schofield P, Turner J, Rauch P, Wakefield C, Mann GB, Newman L, Mason K, Gilham L, Cannell J, and Stafford L
- Subjects
- Adult, Attitude to Health, Breast Neoplasms diagnosis, Child, Child, Preschool, Female, Humans, Middle Aged, Parenting psychology, Psycho-Oncology, Qualitative Research, Victoria, Breast Neoplasms psychology, Communication, Health Personnel psychology, Health Resources, Mothers psychology
- Abstract
Objective: To explore the communication and resource needs of mothers diagnosed with breast cancer treated with curative intent in communicating with their young children and to identify gaps in the resources and support provided to these women., Methods: Data were collected via semi-structured telephone interviews from 13 mothers who were diagnosed with breast cancer while parenting a young child (age 3-12 years), and 10 health professionals in Victoria, Australia. Data were analysed qualitatively using the Framework Method., Results and Conclusion: Mothers and health professionals prioritised communication with children about the cancer diagnosis; however, health professionals and mothers differed in their views of parents' communication needs both in terms of the nature of the support/information needed and the delivery of this support/information. Mothers wanted easily accessible resources that were both instructive and practical. Mothers also emphasised quality over quantity of support. Health professionals were mostly aware of mothers' needs, however, emphasised less instructive support and information. This study highlights the need for improved coordination and tailoring of psychosocial resources and supports for these parents and families communicating about a cancer diagnosis with their young children., (© 2019 John Wiley & Sons Ltd.)
- Published
- 2019
- Full Text
- View/download PDF
49. Experiences and interpretations of BRCA1/2 testing among women affected by breast or ovarian cancer who received a negative result.
- Author
-
Stafford L, Flehr A, Judd F, Lindeman GJ, Gibson P, Komiti A, Mann GB, and Kentwell M
- Abstract
The aim of this study was to retrospectively describe the genetic testing motives and experiences of women with a previous breast and/or ovarian cancer diagnosis, who received negative BRCA1/2 results including variants of unknown significance and no pathogenic variant detected. One hundred and thirteen women (mean age 56.17 years) were recruited from a familial cancer centre in metropolitan Australia, an average 3.4 years after undergoing testing. Participants completed a self-report questionnaire focusing on the retrospective experience of and motives for undergoing BRCA1/2 testing. The study found that the primary motives for undergoing BRCA1/2 testing were (a) to know more about whether their cancer was hereditary, and (b) to have more certainty about the risk of their children developing cancer. In terms of perceptions of personal risk, 35% of women perceived that their risk of breast cancer to be the same or lower than the general population and 80% believed the negative test result to mean that a risk-conferring gene had not been detected. Yet, the average estimate of the likelihood that their cancer was hereditary was 48 out of a possible 100. Psychologically, women did not interpret the negative BRCA1/2 result as a positive outcome. Half were not relieved by the result and were as or more worried than before. Psychological morbidity was high with 17%, 100%, and 36% experiencing clinically significant depression, anxiety, and cancer-specific distress, respectively. Self-ratings of the likelihood that their cancer was hereditary were more closely associated with their personal family cancer histories than with measures of psychological distress. These results have implications for adherence to risk-reducing behaviours and quality of life. Given that these women are not routinely followed up in clinical practice, these findings highlight the importance of post-test genetic counselling and longer-term follow-up for women with negative BRCA1/2 results. Additional time and emotional support from genetic counsellors may help this group of women make sense of the meaning of their test result and adjust psychologically, particularly to uncertainty around the cause of their family history.
- Published
- 2019
- Full Text
- View/download PDF
50. Improving breast cancer screening in Australia: a public health perspective.
- Author
-
Nickson C, Velentzis LS, Brennan P, Mann GB, and Houssami N
- Subjects
- Adult, Aged, Aged, 80 and over, Australia, Early Detection of Cancer statistics & numerical data, Female, Humans, Mass Screening statistics & numerical data, Middle Aged, Public Health statistics & numerical data, Breast Neoplasms diagnosis, Early Detection of Cancer methods, Mass Screening methods, Public Health methods, Quality Improvement organization & administration
- Abstract
There are currently no single disruptors to breast cancer screening akin to the impact of human papillomavirus testing and vaccination on cervical cancer screening. However, there is a groundswell of interest to review the BreastScreen Australia program to consider more risk-based screening protocols and to establish whether to routinely inform women about their breast density. We propose a framework for a considered, evidence-based review. Population-level effectiveness of breast cancer screening is ultimately measured through its impact on breast cancer mortality, and this has been realised in Australia. Effectiveness can also be measured through treatment intensity, estimated overdiagnosis, false-positive screens and health economics measures. Key levers to improve such population-level outcomes include screening participation, screening test sensitivity and specificity, risk assessment and screening protocols. We propose that the review of the program should fall under an evidence-based, consensus-guided framework comprising four complementary elements: improved evidence on current program performance for population risk subgroups; regularly updated evidence on key levers for change; clinical trials and population simulation modelling working in tandem; and consensus-based decision making about the degree of improvement required to justify change. Informing women about their breast density is feasible and would be valued by some BreastScreen clients to help understand the accuracy of their screening test. However, without agreed protocols for screening women with dense breasts, increases in supplemental screening as observed in other settings would, in Australia, shift screening costs to clients and Medicare. This would reduce equity of access to population screening, and maintaining BreastScreen's usual standard of monitoring and quality management (such as screen-detected and interval cancer diagnoses, and imaging and biopsy rates) would require data linkage between BreastScreen and other services. The proposed framework assesses screening effectiveness in the era of personalised medicine, allows review of multiple factors that may together warrant change, and gives full, evidence-based consideration of the benefits, harms and costs of various approaches to breast cancer screening. To be effective, the framework requires a coordinated approach to generating the evidence required for policy makers, with time to prepare appropriate health services., Competing Interests: CN receives salary funding via the project 'Optimising Early Detection of Breast Cancer in Australia', funded by the Australian Department of Health and led by Cancer Council Australia. She jointly leads the development of the AutoDensity automated breast density measurement tool, through a collaboration between the University of Melbourne and the CSIRO. PB is the Chief Executive Officer of the start-up DetectEd-X, which provides radiology training and research.
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.